Stryker Corp. Stock
Stryker Corp. Stock
Pros and Cons of Stryker Corp. in the next few years
Pros
Cons
Performance of Stryker Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stryker Corp. | -0.660% | -2.599% | -2.749% | 17.507% | 16.679% | 46.692% | 96.898% |
| Baxter International | 1.020% | -5.270% | -3.063% | -5.896% | 5.649% | -48.311% | -43.405% |
| Dexcom Inc. | -2.330% | -3.921% | 4.707% | 15.589% | 12.058% | 50.342% | 410.104% |
| Dentsply Sirona Inc. | -1.000% | -5.701% | -5.795% | -24.012% | -11.591% | -47.894% | -34.189% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first impressions of Stryker Corporation's financials (SYK), it appears that the company has displayed relatively stable growth in the burgeoning healthcare equipment and supplies industry. With increasing total assets, revenue, and net income over the past years, Stryker seems to be on a positive trajectory. However, a more in-depth analysis of the financials reveals some areas of concern, as well as some strong points.
*Pros: *
Revenue Growth: Stryker has consistently increased its total revenue over the years, from $14.35 billion in 2020 to $18.45 billion in 2022. This demonstrates the company's ability to expand its market share, sales, and customer base in the industry.
Comments
News
4 med tech stocks with improving prognosis for 2024
Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to
The Value Deepens for Medtech Stocks: Reversal Imminent
Results from Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad